What are the precautions for Tremelimumab?

Tremelimumab is a CTLA-4 monoclonal antibody that enhances the body's anti-tumor immune activity by blocking T cell inhibitory signals. Although this drug has shown potential value in the treatment of some tumors, its application is also associated with a high proportion of immune-mediated toxic reactions. Such adverse events often involve multiple organ systems and can even be life-threatening in severe cases, so they must be carefully monitored and handled promptly in clinical use. The following is a summary of the main related adverse reactions.

1. Immune-mediated pneumonia

Some patients will develop pulmonary inflammatory reactions during treatment, manifesting as cough, shortness of breath, hypoxemia and even imaging abnormalities. Individual cases can develop into severe or fatal pneumonia. Most patients can gradually recover after receiving glucocorticoid treatment, but some require high doses or even combination with other immunosuppressants. Clinically, when respiratory symptoms occur, the patient should be investigated immediately and treatment should be suspended.

2. Immune-mediated colitis and diarrhea

Temsitumumab can cause immune-related damage to the colon mucosa, manifested by frequent diarrhea, abdominal pain, and even bloody stools. Most patients require systemic glucocorticoid therapy, and severe cases often require the addition of stronger immunosuppressants. Although most patients recover with treatment, some cases require permanent discontinuation of medication.

3. Immune-Mediated Hepatitis

The liver is one of the organs that is relatively highly affected. Some patients may experience significant elevations in transaminases, jaundice or even liver failure. Such reactions often require high-dose glucocorticoid treatment, and in some cases combined immunosuppressants are required. If liver function continues to deteriorate, the drug usually needs to be discontinued to avoid more serious consequences.

4. Adrenal insufficiency

Tistumumab can affect the hypothalamus-pituitary-adrenal axis, resulting in insufficient secretion of adrenocortical hormones. Symptoms include fatigue, hypotension, weight loss, etc. In severe cases, acute crisis may occur. Most patients require long-term glucocorticoid replacement therapy, and some cases require high-dose regimens to stabilize the disease.

5. Immune-mediated hypophysitis

Hypophysitis is one of the more typical adverse reactions of temsitumumab. Clinical symptoms include headache, visual field loss or photophobia, and some patients are accompanied by hypopituitarism. Treatment is mainly glucocorticoids, and some patients require long-term endocrine replacement. Some patients have to permanently discontinue the drug due to the potential for irreversible pituitary damage.

6. Thyroid-related reactions

Immune-related thyroiditis is more common and can lead to hyper or hypothyroidism. Patients with abnormal function may require thyroid suppressants, beta blockers, or long-term hormone replacement therapy. Some patients experience "hyperthyroidism first and then decline" and eventually develop permanent hypothyroidism, so their thyroid function needs to be closely followed up.

7. Type 1 diabetes

Some patients develop new-onset diabetes during treatment, some of which are accompanied by diabetic ketoacidosis. These conditions are usually irreversible and patients require long-term insulin therapy. If the condition is severe, the temsitumumab combination regimen should be suspended or permanently discontinued.

8. Immune-mediated nephritis

A small number of patients develop kidney damage, manifested by elevated creatinine or proteinuria. Treatment is still based on systemic glucocorticoids, and some require high-dose regimens. If kidney function fails to recover, treatment will need to be discontinued.

9. Skin related reactions

Skin rash, itching, and dermatitis are common and usually mild to moderate. Severe cases may develop Stevens-Johnson syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), or toxic epidermal necrolysis (TEN). Mild cases can often be controlled with topical corticosteroids and emollients, but severe cases require discontinuation of the drug and systemic treatment.

10. Pancreatitis

Temsitumumab may also cause immune-mediated pancreatitis, with some cases manifesting as acute abdominal pain and elevated serum amylase. Treatment usually requires high-dose glucocorticoid intervention. The condition of most patients can be relieved, but some may relapse.

Reference: https://www.drugs.com/mtm/tremelimumab.html